EWING, N.J., March 31, 2011 /PRNewswire/ — Navinta’s
proprietary complex pharmaceutical ingredient, Sodium Ferric
Gluconate as covered under Navinta’s US Patent 7,179,939 and US
Drug Master File is a key component in the recent approval of
GeneraMedix Inc.’s ANDA for Sodium Ferric Gluconate Complex in
Sucrose Injection, 62.5 mg/5 mL.
The Navinta’s proprietary complex pharmaceutical ingredient
technology provides a platform for preparation of complex
injectable formulations of Iron drug products.
“We are pleased to see commercialization of our innovative
complex pharmaceutical product,” said Dr. Mahendra Patel, Chief
Executive Officer of Navinta, LLC. “Our work represents the
culmination of many years of laboratory and drug development work.
Navinta’s development pipe line targets several such complex
molecules in their development portfolio.”
Navinta, LLC in Ewing, N.J. is a technology driven
Pharmaceutical Company that focuses on novel routes of synthesis of
new and existing drug molecules, complex pharmaceutical
ingredients, novel formulations of liquid dosage form, novel oral
dosage form, novel injectable dosage form and implantable drug
delivery devices. Navinta has currently at least fifteen (15)
patents granted or pending with the United States Patent and